KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.